- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- FDA cites Ranbaxy plant for possible violations
- FDA's Janet Woodcock not to retire
SILVER SPRING, Md. – The Food and Drug Administration is barring the importation of drugs from another one of Ranbaxy Labs' plants in India, the agency said Monday.
The FDA said it had issued an import alert concerning drugs from the plant, in the Indian city of Mohali. An import alert means that customs officials can seize drugs from the plant when they reach the U.S. border, and the agency said the alert would remain in place until the company complies with U.S. drug-manufacturing requirements, known as current good manufacturing practices, or CGMP. Ranbaxy could not be reached for comment.
Mohali is 1-in-3 Ranbaxy manufacturing plants in India under an import alert, the other two being plants in Paonta Sahib and Dewas. The latter two have been under import alerts since 2008. The FDA found "significant CGMP violations" at the Mohali plant during inspections in September and December 2012, including failure to adequately investigate problems or establish procedures to ensure manufacturing quality. The company will be prohibited from selling drugs from the plant in the United States until it has fully addressed the issues to the FDA's satisfaction, the agency said.
"The FDA is committed to using the full extent of its enforcement authority to ensure that drugs made for the U.s. market meet federally mandated quality standards," FDA Center for Drug Evaluation and Research compliance office director Howard Sklamberg said. "We want American consumers to be confident that the drugs they are taking are of the highest quality, and the FDA will continue to work to prevent potentially unsafe products from entering the country."